Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet Oncol · 2026-11-01

In 160 transplant-ineligible adults with relapsed/refractory large B-cell lymphoma, CD20-CD19 CAR T-cell therapy zamto-cel lengthened event-free survival vs R-GemOx (median 6·21 vs 2·53 months; HR 0·39). Treatment-related deaths: 3% vs 1%.

RCTn = 160
Borchmann et al. Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study
Oncology · Lancet · 2026-10-26

In 299 patients with mismatch repair-deficient advanced or recurrent endometrial cancer, first-line pembrolizumab beat carboplatin-paclitaxel on progression-free survival (median 38·2 vs 8·4 months; HR 0·57); overall survival not significant at interim analysis.

RCTn = 299
Slomovitz et al. First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
Oncology · Lancet · 2026-10-26

In 498 patients in China with EGFR-mutated advanced NSCLC progressing after EGFR-TKI therapy, the HER3-directed antibody-drug conjugate ruzaltatug rezetecan improved PFS vs platinum–pemetrexed (median 8·3 vs 5·4 months; HR 0·47) at interim analysis.

RCTn = 498
Xu et al. Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
Oncology · Lancet Oncol · 2026-10-25

Phase 3 trial, 231 patients with locally advanced rectal cancer: short-course radiotherapy, camrelizumab and CAPOX vs long-course chemoradiotherapy then CAPOX. Primary pCR 39.8% vs 15.3%; interim 3-year event-free survival 91.3% vs 77.4% (HR 0.33).

RCTn = 231
Tao et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
Oncology · Lancet · 2026-10-24

In 970 patients with refractory metastatic colorectal cancer in Japan, a 14-day trifluridine-tipiracil plus bevacizumab schedule was non-inferior to the 28-day schedule for overall survival (median 11·3 vs 10·3 months; HR 0·93), with less grade ≥3 neutropenia (13% vs 39%).

RCTn = 970
Sakakida et al. 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan
Oncology · Lancet Oncol · 2026-10-09

In German women aged 50–70, tomosynthesis plus synthesised 2D mammography did not significantly reduce 24-month invasive interval breast cancer versus digital mammography (14·2 vs 18·6 per 10 000 screen-negative women; OR 0·76, 95% CI 0·55–1·06).

RCTn = 98,755
Weigel et al. Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial
Oncology · Lancet Oncol · 2026-10-01

Prespecified 10-year analysis of 810 women with high-risk breast cancer after mastectomy: locoregional recurrence was 12.0% with hypofractionated (43.5 Gy/15) vs 10.3% with conventional (50 Gy/25) radiotherapy (HR 1.19, 0.79-1.82); grade 3 late toxicity was rare in both.

RCTn = 810
Sun et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial
Oncology · Lancet Oncol · 2026-09-25

In relapsed/refractory myeloma after 1–2 prior lines, iberdomide-daratumumab-dexamethasone raised MRD-negative complete response vs daratumumab-bortezomib-dexamethasone (41% vs 21%; OR 2·8). Grade 3–4 events 92% vs 70%; PFS still pending.

RCTn = 420
Lonial et al. Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
Oncology · J Clin Oncol · 2026-09-24

In 731 patients with untreated advanced HER2-negative gastric/GEJ adenocarcinoma, retlirafusp alfa plus CAPOX improved OS vs placebo plus CAPOX (median 15.8 vs 11.2 months, HR 0.66; CPS ≥5: 16.8 vs 10.4, HR 0.53). Grade ≥3 toxicity similar.

RCTn = 731
Peng et al. First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)
Oncology · J Clin Oncol · 2026-09-16

Secondary analysis of a partially randomised patient-preference trial in 587 distressed cancer survivors: vs waitlist, mindfulness-based cancer recovery and Tai Chi/Qigong both improved fatigue and pain interference. Only Tai Chi improved sleep, and the two did not differ.

Secondary analysisn = 587
Ma et al. Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.